Clinical trial NCT00910351: Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
Official title: A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin in Adults and Children Aged 6 - 12 Years With Cystic Fibrosis Following Inhalation of Ciprofloxacin Dry Powder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pseudomonas Infection
Keywords: Cystic Fibrosis
Pharmacokinetics
Pediatrics
Inhalation
Sputum
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-05-29
Enrollment: 19
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.


Eligibility criteria: Inclusion Criteria:

* Male or female patients with cystic fibrosis confirmed by genetic testing and / or by sweat test
* Colonization with P. aeruginosa confirmed in sputum in the past 12 months
* Cohort 1: greater than or equal to 18 years of age.
* Cohort 2: 6 - 12 years of age (inclusive)
* Normal Body Mass Index: BMI between 14.5 and 30 kg/m2, but in no case lower than the 30th percentile for age. Because CF patients are typically smaller than non-CF-patients, the normal body mass index will be based on standard CF foundation normal values for weight and sex.
* Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period.
* Patients and legal representatives must have given their written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures

Exclusion Criteria:

* Patients with FEV1 \< 35% of predicted. FEV1 (forced expiratory volume) is a measure of lung function. This exclusion will prohibit enrollment of patients with severely impaired lung function.
* Patients with Burkholderia cepacia colonization of their respiratory tract
* Patients with acute bronchopulmonary aspergillosis (ABPA)
* Patients on a lung transplant list
* Patients with acute pulmonary exacerbations
* Patients with severe liver cirrhosis
* Massive hemoptysis in the preceding 4 weeks
* A history of relevant diseases of vital organs, of the central nervous system, or other organs not related to the underlying disease
* Patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies
* Patients with hypersensitivity to the investigational drug or to other quinolones and/ or to inactive constituents
* Patients with known intolerance to hypertonic saline or bronchodilators
* Concomitant inhalation therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones
* Women who are pregnant

Primary outcomes:
measure: To investigate the safety and tolerability of inhaled ciprofloxacin given as single inhalation dose to pediatric CF patients, aged 6 - 12 years
timeFrame: Two weeks post screening
Secondary outcomes:
measure: To investigate the pharmacokinetics of ciprofloxacin in plasma and sputum after inhalation administration
timeFrame: Day 1
Other outcomes:
Locations:
city: Atlanta
country: United States
state: Georgia
city: Baltimore
country: United States
state: Maryland
city: Boston
country: United States
state: Massachusetts
city: Syracuse
country: United States
state: New York
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: